BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12016154)

  • 1. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors.
    Hemminki K; Jiang Y; Ma X; Yang K; Egevad L; Lindblad P
    Carcinogenesis; 2002 May; 23(5):809-15. PubMed ID: 12016154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of renal carcinoma: the nutri-genetic approach].
    Junien C; Dupret JM; Gallou C; Longuemaux S; Richard S; Saquet C; Krishnamoorty R; Delomenie C; Droz D; Bouvier R; Chauveau D; Joly D; Grunfeld JP; Chretien Y; Mejean A; Beroud C
    J Soc Biol; 2000; 194(1):29-38. PubMed ID: 11107547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
    Zbar B
    Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
    Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
    Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status.
    Ashida S; Furihata M; Tanimura M; Sugita O; Yamashita M; Miura T; Moriyama M; Shuin T
    J Urol; 2003 Jun; 169(6):2089-93. PubMed ID: 12771725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.
    Gallou C; Chauveau D; Richard S; Joly D; Giraud S; Olschwang S; Martin N; Saquet C; Chrétien Y; Méjean A; Correas JM; Benoît G; Colombeau P; Grünfeld JP; Junien C; Béroud C
    Hum Mutat; 2004 Sep; 24(3):215-24. PubMed ID: 15300849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma.
    Igarashi H; Esumi M; Ishida H; Okada K
    Cancer; 2002 Jul; 95(1):47-53. PubMed ID: 12115316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma.
    Ashida S; Okuda H; Chikazawa M; Tanimura M; Sugita O; Yamamoto Y; Nakamura S; Moriyama M; Shuin T
    Clin Cancer Res; 2000 Oct; 6(10):3817-22. PubMed ID: 11051223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
    Koochekpour S; Jeffers M; Wang PH; Gong C; Taylor GA; Roessler LM; Stearman R; Vasselli JR; Stetler-Stevenson WG; Kaelin WG; Linehan WM; Klausner RD; Gnarra JR; Vande Woude GF
    Mol Cell Biol; 1999 Sep; 19(9):5902-12. PubMed ID: 10454537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
    Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
    Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells.
    Gorospe M; Egan JM; Zbar B; Lerman M; Geil L; Kuzmin I; Holbrook NJ
    Mol Cell Biol; 1999 Feb; 19(2):1289-300. PubMed ID: 9891063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.
    Ma X; Yang K; Lindblad P; Egevad L; Hemminki K
    Oncogene; 2001 Aug; 20(38):5393-400. PubMed ID: 11536052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
    Gallou C; Joly D; Méjean A; Staroz F; Martin N; Tarlet G; Orfanelli MT; Bouvier R; Droz D; Chrétien Y; Maréchal JM; Richard S; Junien C; Béroud C
    Hum Mutat; 1999; 13(6):464-75. PubMed ID: 10408776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma.
    Hamano K; Esumi M; Igarashi H; Chino K; Mochida J; ISHIDA And H; Okada K
    J Urol; 2002 Feb; 167(2 Pt 1):713-7. PubMed ID: 11792959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.